249 filings
Page 7 of 13
8-K
oa9yc6sq4l0
3 Mar 15
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial and Operational Results
12:00am
8-K
jj0fp
12 Feb 15
Entry into a Material Definitive Agreement
12:00am
8-K
1ewqtpdvacryj3bwvsbh
7 Jan 15
Departure of Directors or Certain Officers
12:00am
8-K
818tg8e
12 Nov 14
Other Events
12:00am
8-K
nco9bfnx dfu7e1ma
3 Nov 14
Results of Operations and Financial Condition
12:00am
8-K
qxclo
9 Oct 14
Other Events
12:00am
8-K
brlr5bc mt
22 Sep 14
Other Events
12:00am
8-K
s88cs ol3yvoanuw3ym4
1 Aug 14
Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
12:00am
8-K
30z224 vj1vm3
2 Jun 14
Threshold Announces Data from Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (AvastinĀ®) in Patients with Recurrent Glioblastoma
12:00am
8-K
amjg2rz ys7j
21 May 14
Departure of Directors or Certain Officers
12:00am
8-K
95n09swzw
1 May 14
Threshold Pharmaceuticals Reports First Quarter 2014 Financial and Operational Results
12:00am
8-K
rawehz291lmb2 b596
6 Mar 14
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
12:00am
8-K
qnp1sy nvtlybf8
2 Jan 14
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
12:00am
8-K
dtza zz7b2pey
11 Dec 13
Other Events
12:00am
8-K
r152w
4 Nov 13
Threshold Pharmaceuticals Reports Third Quarter 2013 Financial and Operational Results
12:00am
8-K
j3mzec9srojbgwg
22 Oct 13
Other Events
12:00am
8-K/A
a99b6pfgn knfo4ckp8
30 Sep 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
wx2vb6p 7bflhgyex5
1 Aug 13
Threshold Pharmaceuticals Reports Second Quarter 2013 Financial and Operational Results
12:00am
8-K
i1jksnoulpvu5thzshc8
1 Jul 13
Other Events
12:00am
8-K
csx5c2mb viqw
3 Jun 13
Other Events
12:00am